of glucose counterregulatory mechanisms and to suppress increased lactate production.
There is a high incidence of secondary skeletal problems in patients with GSD 1, 2-4 including decreased bone mass. 2, 3 Quantitative evaluation of bone samples obtained at autopsy revealed a severely decreased amount of both cancellous and cortical bone, but there was no evidence for a mineralization defect (osteomalacia). 4 However, all of these studies examined patients who did not receive treatment according to current protocols. 5, 6 In a survey of adults with GSD 1, osteopenia or pathologic fractures were found in about one third 7 ; yet, most of these patients had not received standard treatment during childhood and adolescence. The beneficial effect of current therapeutic approaches on skeletal development is evidenced by improved longitudinal growth. 8 One study of children with GSD 1 found that bone mass at the radius was below average in 10 of 11 patients. 9 A similar trend was shown in a preliminary report of 23 patients. 10 Glycogen storage disease type 1 (GSD 1) is a heterogeneous disease caused by deficiency in the glucose-6-phosphatase (G-6-Pase) system as the result of molecular defects in the genes for either G-6-Pase (GSD 1a) or glucose-6-phosphate translocase (GSD 1b MD to grow, and hyperuricemia and later have delayed puberty and bone maturation and kidney disease. In GSD 1b, additional infectious complications result from neutropenia and impaired neutrophil and monocyte function. 1 The goal of therapy is to provide sufficient amounts of dietary glucose to maintain plasma glucose concentrations above the threshold for activation Objective: To study the relation between muscle force, bone mass, and metabolic control in patients with glycogen storage disease type (GSD 1).
Study design: Distal radius bone mass and density were evaluated in 19 patients with GSD 1 (15 GSD 1a, 4 GSD 1b) by means of peripheral quantitative computed tomography. Grip force was quantified with a dynamometer.
Results: Height, weight, bone mass, and grip force were significantly decreased in the patients with GSD 1a, mainly as the result of low values in the poorly controlled subgroup. Boys had lower bone mass than girls. Patients with GSD 1b had higher values for bone mineral density in the trabecular compartment. In most of the study participants bone mass appeared to be adequately adapted to the mechanical requirements imposed by muscle contraction. However, 3 patients with GSD 1a had evidence for a low bone mass.
Conclusions:
In GSD 1, both reduced muscle strength and a direct disease effect can contribute to low bone mass. The quality of treatment is crucial to prevent disturbances in musculoskeletal development. THE JOURNAL OF PEDIATRICS SCHWAHN ET AL VOLUME 141, NUMBER 3
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Low muscle mass was noted in a proportion of patients with GSD 1 who were not continuously treated according to current protocols. 3, 7 Thus it is possible that low bone mass was the result of decreased mechanical stimulation. We therefore evaluated distal radius bone mass and density as well as maximal isometric grip force in a group of 19 patients with GSD 1; in addition, we analyzed the influence of metabolic control.
METHODS

Patients
Fifteen patients with GSD 1a and 4 with GSD 1b (7 female, 12 male), all diagnosed in early childhood, were allocated to a "well controlled" (GSD 1a+) group and a "poorly controlled" (GSD 1a-) group. Patient 1 had to be excluded for some analyses because of his low bone age. The well-controlled group had been continuously treated with a carefully adapted carbohydratebalanced regimen, including nocturnal nasogastric drip feeding of glucose polymer, which was designed by an experienced dietician to meet recommended intakes for nutrients, minerals, and vitamins. Regular visits in the outpatient clinics and routine hospitalizations for metabolic check-ups including blood and two 12-hour urine collections provided long-term data that showed satisfactory metabolic control with preprandial and nocturnal blood glucose concentrations in the high normal range (4.3-5.5 mmol/L), lactate concentrations in urine in the low normal range (0.042 ± 0.020 mol/L creatinine, normal range <0.06 mol/L), and only slightly elevated triglyceride levels. These patients have been described in detail elsewhere. 11 The 4 patients, designated as the poorly controlled group, went either through a prolonged period of less intensive therapy in early childhood (patients [12] [13] [14] or discontinued adequate therapy later (patient 15). All four provided clinical and laboratory evidence for a nonsatisfactory glycemic control with increased lactic aciduria and reported difficulties in following the recommended dietary treatment. The group of patients with GSD 1b was too small to be divided. One patient in this group (patient 19) would have been considered as poorly controlled by the above criteria.
Pubertal and skeletal development of the patients are described in Table  I . 12, 13 Only one of the patients was active in sports (patient 9), but all patients reported normal physical activity. None had a history of bone fractures, muscular weakness or fatigue, or a family history of bone disease. Almost all received allopurinol (2-5 mg/kg) because of hyperuricemia. In the GSD 1b group, two patients (patients 16 and 19) were treated with granulocyte-colony stimulating factor for several years. All patients and parents, respectively, gave written informed consent to this study, which was approved by the Ethics Committee of the Heinrich-Heine-University at Düsseldorf. Bone age was assessed with plain radiographs of the left hand and wrist according to Greulich and Pyle. 12 Tanner stages were determined by grading system defined by Tanner. 13 Age at menarche was not available for patient 10 and was obtained after completing the study for patients 16 and 17.
Methods
Height was measured with an Ulmer stadiometer (Prof Heinze, Ulm, Germany). Body mass was measured with a digital electronic scale. Forearm length was measured as the distance between the ulnar styloid process and the olecranon with the use of a caliper.
Bone mass and density of the nondominant side were measured by peripheral quantitative computed tomography (XCT 900; Stratec Medizintechnik GmbH, Pforzheim, Germany). Bone mineral content (BMC, mg/mm) and volumetric trabecular bone mineral density (BMDtrab, mg/cm 3 ) were automatically analyzed from the tomographic image with the use of the manufacturer's software (version 5.20). BMDtrab was defined as the mean mineral density of the 45% core area of the bone cross section at the site of the radius, whose distance to the medial border of the distal radial articular cartilage corresponded to 4% of forearm length. BMC corresponds to the mass of mineral contained in the entire tomographic slice, normalized to 1.0-mm thickness. Maximal isometric grip force of the nondominant hand was determined with a standard adjustable-handle Jamar dynamometer (Preston, Jackson, Miss), as described in by Neu et al. 14 Serum and urine were collected 0 to 4 weeks before the peripheral quantitative computed tomography (pQCT) evaluation. Serum and urine samples was obtained from 11 patients (4 with GSD 1a+; 4 with GSD 1a-; 3 with GSD 1b). Samples were frozen immediately after collection and stored at -20°C until analysis. Intact parathyroid hormone was measured by means of a chemiluminescence method (PTH Intact; Nichols Institute, San Juan Capistrano, Calif). Serum procollagen type 1 carboxyterminal propeptide was measured by radioimmunoassay (Orion Diagnostica, Turku, Finland). 15 Urinary concentrations of deoxypyridinoline were determined with a chemiluminescence assay (IMMULITE Pyrilinks-D; Diagnostic Products Corp; Los Angeles, Calif). Results are expressed relative to urinary creatinine concentrations.
Statistical Analyses
Height, weight, body mass index (BMI), BMC, BMDtrab, and grip force results are expressed as z scores, with the use of recently established reference data. 14 Comparisons of mean z scores of patients with normal population data was done with a 1-sample t test; comparisons between means of two patient groups were done by 1-way analysis of variance followed by individual 2-tailed t tests. Throughout the study, a value of P < .05 was considered significant.
RESULTS
Two of 11 patients in the GSD 1a+ group and all 4 patients in the GSD 1a-group showed a delay in skeletal maturation between 1.1 and 2.5 years. Patient 15 had retarded onset of puberty (Table  II) . The significant decrease in height and weight of patients with GSD 1a was mainly due to low values in the GSD 1a-subgroup, although 3 of the GSD 1a+ patients were short (height Z score <-2). Also, 2 of the patients with GSD 1b were short. BMI was normal in all except 1 patient with GSD 1a-, who was obese. Individual results of musculoskeletal analyses are presented in Fig 1. BMC was below average in all except 1 of the boys, whereas in girls the results were evenly distributed around the age-specific mean value. With boys and girls combined, BMC was significantly decreased in the GSD 1a group (Table II) , but this was entirely due to the low result in boys. The difference between girls and boys was similar when only the patients with a satisfactory metabolic situation were considered (not shown).
BMDtrab was slightly below the reference range in 2 of the boys with GSD 1a+ and was elevated in 1 girl with GSD 1a+ and 1 boy with GSD 1b (Fig  1) . BMDtrab Z score did not significantly deviate from 0 in the entire GSD 1a group. However, values in boys were significantly decreased. The results were similar when only the patients with GSD 1a+ were analyzed.
Grip force was low in the patients who were classified as GSD 1a- (Fig  1) , which explained the significant decrease in grip force Z score in the whole GSD 1a group. Grip force also was below average in all 4 patients with GSD 1b (Fig 1) . The relation between bone mass and muscle force can be judged from Fig 2 and is compared with the results in healthy subjects from 5.5 to 19.5 years of age. Most of the patients had results for grip force and BMC that were close to the regression line in the healthy population, suggesting that bone mass was normally adapted to the mechanical requirements. However, in 3 boys from the GSD 1a+ group, BMC appeared to be Values are median (range) for each parameter. Apart from age, all results are given as Z scores. *Significant difference of the SDS from 0 (calculations done only in the GSD 1a and GSD 1a+ groups; other groups were too small to obtain meaningful results). Table III . Anthropometric data and results of musculoskeletal analyses in patients with GSD 1 after adjustment for bone age GSD 1a GSD 1a+ GSD 1a-GSD 1b low for the level of grip force (marked by arrows in Fig 2) . Retarded skeletal development is a well-known phenomenon in patients with GSD 1. Because retardation was more pronounced in the poorly controlled group (Table I) , we reevaluated the anthropometric and musculoskeletal data after adjustment to the respective bone age to avoid a bias toward lower Z scores in the patients with GSD 1a-. Patient 1 had to be excluded for this analysis because of lacking reference values for the low corrected age. The mean adjusted Z scores were clear-354 ly higher for height and weight, and, less pronounced, for BMI and BMC in the GSD 1a-group (Table III) compared with Z scores derived from data that used the chronologic age (Table  II) . The values for BMDtrab increased in the GSD 1a+ group; however, other results remained unchanged. Sex-related differences in patients with GSD 1a after adjustment for bone age are presented in Fig 3. Because of a more pronounced increase of height in boys after correction, girls now had a significantly lower mean height Z score than boys. BMC and BMDtrab were significantly higher in girls, similar to the differences obtained with uncorrected data.
Hypercalcemia (total calcium at 2.97 mmol/L) was present in one patient from the GSD 1a+ group; hypocalcemia (1.92 mmol/L) was noted in one patient with GSD 1b. Serum phosphorus was in the lower part of the reference range for most patients. Serum levels of parathyroid hormone and 25-OH vitamin D were within the reference range for all patients. Hypercalciuria (urinary calcium/creatinine ratio >0.19 mg/mg) was noted in 3 patients with GSD 1a, two of whom were classified as GSD 1a-. Markers of bone metabolism did not show any consistent abnormalities (not shown). Both serum procollagen type 1 carboxyterminal propeptide, a marker of collagen synthesis and bone formation, and the urinary deoxypyridinoline/creatinine ratio, a marker of bone resorption, were within the reference ranges for all except one patient. 15 
DISCUSSION
In this cross-sectional study we analyzed bone mass, density, and metabolism as well as muscle force in children and adolescents with GSD 1. During childhood and adolescence, the skeleton must continually adapt to increasing mechanical requirements. The largest mechanical challenge to bone is created by muscle contraction, which puts a far larger load on bones than simple gravity. 16, 17 Consequently, low bone mass can be caused by either decreased mechanical requirements or by inadequate adaptation to these requirements. 18 The muscle system was therefore taken into account in the current study to allow for some discrimination between direct disease effects on bone mass and secondary effects, which may result from insufficient mechanical stimulation. 19 Lee et al 9 used single-photon absorptiometry to measure BMC at the radial shaft, whereas in the current study pQCT was used to analyze the radius at a metaphyseal site. This enabled us to quantify not only BMC but also the volumetric mineral density of the trabecular compartment.
None of our patients had grossly decreased BMC and none had sustained fractures. Average BMC was moderately low, but this decrease was limited to boys, whereas all girls had a BMC close to or above the age-specific mean value. The difference between the sexes is in contrast to the observations of Lee at al. 9 This may simply be the effect of chance as the result of the small number of subjects in both studies or may reflect differences in the sites of measurement. In contrast to BMC, grip force Z score was similar for boys and girls or, after correction for bone age, even slightly higher in boys than in girls. This indicates that if real, the sex difference in BMC could be caused by a difference in the direct effect of the disease on bone. There are sex-related differences in bone adaptation to muscle force: 4 of 5 girls with GSD 1a had a BMC above the regression line for healthy individuals, whereas this was true for only 1 of 10 boys. Nevertheless, in most patients BMC was adequate for grip force. In accordance with this, both grip force and BMC were low in patients with GSD 1a with inadequate metabolic control. In these patients, lack of mechanical stimulation is likely to have contributed to low bone mass. Though only one of the patients in our study was active in sports, all others participated in regular activities of daily life, including physical education at school as did their peers, and no overt clinical signs of muscular weakness were detectable. Thin extremities have been described in untreated patients with GSD 1 and muscle atrophy has been stated on plain radiographs. 3 Eight of 37 adults with GSD 1a had symptoms of muscle weakness in another study. 7 Skeletal muscle does not express G-6-Pase activity; however, it is the major site for insulindependent glucose disposal in vivo. 1 A number of important muscle genes are under the control of insulin. 20 Chronic hypoinsulinism and elevation of counterregulatory hormones as the result of impaired hepatic glucose output have been hypothesized in GSD 1, 1 which could contribute to both disturbed energy supply and altered gene expression in skeletal muscle. Moreover, profound effects of an altered carbohydrate homeostasis 21 and of metabolic acidosis 22, 23 on protein turnover or exercise performance 24 of skeletal muscle have been demonstrated. Subclinical muscle weakness in adequately treated patients with GSD 1 has not been sufficiently explored.
In the GSD 1b group, BMDtrab was comparatively high. We obviously cannot exclude that this is a chance finding as the result of small numbers. However, two studies have reported increased cellularity and decreased fat marrow in the bone of patients with GSD 1b. 25, 26 Although marrow composition in itself does not affect the amount of mineral per unit volume of the trabecular compartment, hemopoietic marrow absorbs more radiation than fat marrow. 27 pQCT might therefore overestimate the actual BMDtrab (and BMC) if fat marrow is replaced by hemopoietic marrow.
Even patients who had received optimal care tended to be shorter than their healthy peers. 8, 9 An alternative therapeutic approach with long-term application of cornstarch also did not result in growth normalization. 28 Short stature in our study was more pronounced in the patients with GSD 1a with an inadequately controlled metabolic situation, highlighting the importance of strict compliance to the treatment regimen. However, this difference appeared for the most part to be the result of retarded skeletal maturation and can therefore be expected to decrease after puberty.
Parameters of calcium and phosphorus homeostasis revealed no major disturbances. Hypercalciuria was present in a number of patients, notably in 2 of the 4 patients with GSD 1a who did not have optimal metabolic control. These observations confirm the findings of 3 other studies 9, 29, 30 but are at variance with the results of calcium kinetics studies in 3 adolescent girls with GSD 1a 31 who had decreased calcium excretion. Chronic hypercalciuria increases the dietary calcium requirements and could contribute to the development of low bone mass.
In accordance with Lee et al, 9 we detected no abnormalities in bone metabolism. This is in contrast to the previously mentioned calcium kinetics study in which increased bone turnover was found in all 3 patients with GSD 1a. 31 Nevertheless, systemic bone markers depend on a number of factors other than bone turnover, such as bone mass, metabolic clearance, and muscle mass (when urinary markers are related to creatinine). 32 To gain a more precise understanding of bone metabolism in GSD 1, direct examination of bone turnover in tetracycline-labeled bone biopsy specimens is required.
In conclusion, in GSD 1a both reduced muscle strength and a direct disease effect can contribute to low bone mass. The quality of treatment is crucial to prevent disturbances in muscle and bone development.
